- Home
- MRNS vs PRE Comparison
MRNS vs PRE Comparison
Compare MRNS & PRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRNS
- PRE
- Stock Information
- Founded
- MRNS 2003
- PRE 2014
- Country
- MRNS United States
- PRE Hong Kong
- Employees
- MRNS N/A
- PRE N/A
- Industry
- MRNS Biotechnology: Pharmaceutical Preparations
- PRE Biotechnology: Laboratory Analytical Instruments
- Sector
- MRNS Health Care
- PRE Industrials
- Exchange
- MRNS Nasdaq
- PRE Nasdaq
- Market Cap
- MRNS 29.9M
- PRE 69.7M
- IPO Year
- MRNS 2014
- PRE N/A
- Fundamental
- Price
- MRNS $0.54
- PRE $5.81
- Analyst Decision
- MRNS Buy
- PRE Buy
- Analyst Count
- MRNS 12
- PRE 1
- Target Price
- MRNS $4.28
- PRE $9.00
- AVG Volume (30 Days)
- MRNS 3.2M
- PRE 11.0K
- Earning Date
- MRNS 03-04-2025
- PRE 11-27-2024
- Dividend Yield
- MRNS N/A
- PRE N/A
- EPS Growth
- MRNS N/A
- PRE N/A
- EPS
- MRNS N/A
- PRE N/A
- Revenue
- MRNS $31,466,000.00
- PRE $25,561,362.00
- Revenue This Year
- MRNS $14.97
- PRE $50.97
- Revenue Next Year
- MRNS $57.65
- PRE $217.53
- P/E Ratio
- MRNS N/A
- PRE N/A
- Revenue Growth
- MRNS 1.63
- PRE N/A
- 52 Week Low
- MRNS $0.22
- PRE $2.85
- 52 Week High
- MRNS $10.50
- PRE $7.84
- Technical
- Relative Strength Index (RSI)
- MRNS 70.61
- PRE 59.58
- Support Level
- MRNS $0.53
- PRE $5.27
- Resistance Level
- MRNS $0.56
- PRE $5.77
- Average True Range (ATR)
- MRNS 0.03
- PRE 0.27
- MACD
- MRNS 0.02
- PRE -0.03
- Stochastic Oscillator
- MRNS 94.94
- PRE 76.62
About MRNS Marinus Pharmaceuticals Inc.
Marinus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. Marinus manages the business in one segment, which is the identification and development of neuropsychiatric therapeutics. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19-RE.
About PRE Prenetics Global Limited
Prenetics Global Ltd is a health sciences company dedicated to consumer and clinical health. Its consumer initiative is led by IM8, a new health and wellness brand, and Europa, a U.S. sports distribution company. The clinical division is led by Insighta, focused on multi-cancer early detection technologies. This is followed by ACT Genomics, which has achieved FDA clearance for genomic profiling of solid tumors, and CircleDNA, which uses NGS to offer DNA tests. Each Prenetics unit impacts health by 'enhancing life through science'.